Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 413 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
Patents for C07D 413 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms (64,687)
10/2005
10/13/2005WO2005094329A2 Compouns, compositions, processes of making, and methods of use related to inhibiting macrophage migration inhibitory factor
10/13/2005WO2005085239A3 PYRROLE-DERIVATIVES AS FACTOR Xa INHIBITORS
10/13/2005WO2005040139A3 2-aminoaryloxazole compounds as tyrosine kinase inhibitors
10/13/2005WO2005021536A3 Adamantane and azabicyclo-octane and nonane derivatives, process of their preparation and their use as dpp-iv inhibitors
10/13/2005WO2004071447A9 Substituted azole derivatives as therapeutic agents
10/13/2005US20050228182 e.g., N-(3,5-diamino-6-chloropyrazine-2-carbonyl)-N'-(4-{4-[3-(1H-tetrazol-5-yl)propoxy]phenyl}butyl)guanidine hydrochloride; used to hydrate mucosal surfaces; are absorbed less rapidly, prolonged pharmacodynamic half-life; chronic bronchitis, cystic fibrosis, sinusitis, dry eye, mucus clearance
10/13/2005US20050228179 Thionation of a carbonyl compound comprising a nitrile group, the presence of a decoy agent comprising a nitrile group
10/13/2005US20050228044 benzodihydrofurans; high activity at PPAR alpha receptor; no activity at PPAR gamma and PPAR delta receptors; atherosclerosis, obesity, and vascular restenosis; 5-{3-[2-Chloro-4-(2,2,2-trifluoro-ethoxy)-phenoxy]-propoxy}-2-methyl-2,3-dihydro-benzofuran-2-carboxylic acid; no 1,3-thiazolidinedione moiety
10/13/2005US20050228036 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
10/13/2005US20050228018 Chemical compounds
10/13/2005US20050228016 Tetrahydroquinolines for modulating the expression of exogenous genes via an ecdysone receptor complex
10/13/2005US20050228015 Substituted heteroaryl- and phenylsulfamoyl compounds
10/13/2005US20050228005 Protein kinase inhibitors and uses thereof
10/13/2005US20050228000 of the coagulation cascade or contact activation system: thrombin, factor Xa, factor XIa, factor IXa, factor VIIa or plasma kallikrein; e.g. -(6-carbamimidoyl-1H-indol-3-ylmethyl)-4-methoxy-biphenyl-2-carboxylic acid; anticoagulant, antiinflammatory agent
10/13/2005US20050227994 Decomposition inhibitor for extracellular matrix of cartilage
10/13/2005US20050227987 11beta-hydroxysteroid dehydrogenase inhibitors
10/13/2005US20050227986 Vanilloid receptor ligands and their use in treatments
10/13/2005US20050227981 Aralkyl and aralkylidene heterocyclic lactam and imides
10/13/2005US20050227980 Aralkyl and aralkylidene heterocyclic lactam and imides
10/13/2005US20050227975 Treatment of inflammatory and obstructive respiratory complaints; 1-{3-[2-hydroxy-2-(6-hydroxy-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-8-yl)-ethylamino]-3-methyl-butyl}-6-methoxy-4,4-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one; potent, high degree of selectivity to the beta 2-adreno-receptor
10/13/2005US20050227971 Thioamide derivatives as progesterone receptor modulators
10/13/2005US20050227970 3-Benzyl-2-(4-trifluoromethyl-3-pyridylcarbonyl)imino-4-thiazolidone; durability; low concentrations; good spectrum of action; insecticides; miticides; nematocides; helminths
10/13/2005US20050227960 N-[(octahydrocyclopenta[c] pyrrol-5-ylcarbamoyl)methyl]-3 -trifluoromethylbenzamide trifluoroacetic acid salt; monocyte chemotactic proteins (MCP-1) receptor antagonist or partial agonists; antiinflammatory agent, antiallergen, autoimmune diseases; rheumatoid arthritis, atherosclerosis, asthma
10/13/2005US20050227914 hydrolysis of methyl 4-[5-(4-pentyloxyphenyl)isoxazol-3-yl]benzoate with potassium hydroxide, then reacting the potassium salt with hydrochloric acid, to form 4-[5-(4-pentyloxyphenyl)isoxazol-3-yl]benzoic acid, used as intermediates for peptide antibiotics; echinocandin derivatives
10/13/2005US20050224524 Aerosol
10/13/2005DE102004010194A1 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate, ihre Herstellung und Verwendung in Arzneimitteln 4-benzimidazole-2-yl-pyridazin-3-one derivatives, their preparation and use in medicaments
10/13/2005CA2563038A1 Neurologically-active compounds
10/13/2005CA2562126A1 Pyrazine derivatives and pharmaceutical use thereof
10/13/2005CA2562106A1 Isoxazole- and isothiazole-amine compounds for the treatment of neurodegenerative disorders
10/13/2005CA2561977A1 Substituted thiophene derivatives as anti-cancer agents
10/13/2005CA2560936A1 Process for producing 5-hydroxy-4-thiomethylpyrazole compound
10/13/2005CA2560691A1 Tricyclic pyrazole kinase inhibitors
10/13/2005CA2560256A1 Heteroaryl piperidine glycine transporter inhibitors
10/13/2005CA2559948A1 Beta-aminoacid-derivatives as factor xa inhibitors
10/13/2005CA2559945A1 Pyrazole compounds and uses related thereto
10/13/2005CA2558915A1 Pyrimidine derivatives and methods of treatment related to the use thereof
10/13/2005CA2557719A1 4- (sulfanyl-pyrimidin-4-ylmethyl) -morpholine derivatives and related compounds as gaba receptor ligands for the treatment of anxiety, depression and epilepsy
10/13/2005CA2557402A1 Pentafluorosulfanyl compounds, their manufacture and use as pharmaceutical agents
10/13/2005CA2557393A1 Oxidized thioether derivatives of styryl-azoles and their use as her tyrosine kinases inhibitors
10/13/2005CA2557372A1 Diaminopyrimidines as p2x3 and p2x2/3 antagonists
10/13/2005CA2557166A1 Compounds, compositions, processes of making, and methods of use related to inhibiting macrophage migration inhibitory factor
10/12/2005EP1584619A1 Derivatives of quinoline as inhibitors for MEK
10/12/2005EP1583763A1 Benzoazolypiperazine derivatives having mglur1- and mglur5-antagonistic activity
10/12/2005EP1583761A1 METHOD FOR PRODUCING 5-CHLORO- i N /i -({5 i S /i )-2-OXO-3- 4-(3-OXO-4-MORPHOLINYL)-PHENYL -1,3-OXAZOLIDIN-5-YL&rc ub;-METHYL)-2-THIOPHENE CARBOXAMIDE
10/12/2005EP1583760A2 Substituted heterocyclic compounds
10/12/2005EP1583755A1 Thiophene-carboxamide derivatives and their use as inhibitors of the enzime ikk-2
10/12/2005EP1583749A1 Oxazole derivatives as inhibitors of cyclooxygenase
10/12/2005EP1583745A1 1-propanol and 1-propylamine derivatives and their use as glucocorticoid ligands
10/12/2005EP1583744A2 Substituted benzylamine derivatives and methods of use
10/12/2005EP0977563B1 Synthesis of epothilones, intermediates thereto, analogues and uses thereof
10/12/2005EP0954522B1 Novel substituted naphthopyrans
10/12/2005EP0794774B1 4,4-(disubstituted)cyclohexan-1-ols monomers and related compounds
10/12/2005CN1681810A Novel oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors
10/12/2005CN1681809A Novel isothiazole and isoxazole compounds as transforming growth factor (TGF) inhibitors
10/12/2005CN1681808A N-substituted-1H-indol-5-propionic acid compounds as PPAR agonists useful for the treatment of diabetes
10/12/2005CN1681805A Novel imidazole compounds as transforming growth factor (TGF) inhibitors
10/12/2005CN1681795A Pyrimidyl sulphone amide derivatives as chemokine receptor modulators
10/12/2005CN1681784A Azabicyclo derivatives as muscarinic receptor antagonists
10/12/2005CN1681503A Sulphonylpiperidine derivatives containing an aryl or heteroaryl group for use as matrix metalloproteinase inhibitors
10/12/2005CN1681502A Novel triazole compounds as transforming growth factors (TGF) inhibitors
10/12/2005CN1681501A Novel pyrazole compounds as transforming growth factor (TGF) inhibitors
10/12/2005CN1681498A Diaryl ethers as opioid receptor antagonist
10/12/2005CN1680338A Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
10/12/2005CN1680333A Anti-virus pyrazole derivatives
10/12/2005CN1680314A 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses
10/12/2005CN1222521C Proces for synthesis of 5-(4-fluorophenyl)-1-[2R, 4R]-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxypic acid phenylamide
10/12/2005CN1222520C Inhibitors of c-JUN N-terminal kinase (JNK) and other protein kinases
10/12/2005CN1222511C I-aryl-or-I-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-b ligands
10/12/2005CN1222287C Pharmaceutical formulations contg. zolmitriptan
10/11/2005US6953858 A phenylalkyl secondary- and tertiary-amides enzyme inhibitors as viricides, for treating AIDS
10/11/2005US6953857 Oxybenzamide derivatives useful for inhibiting factor Xa or viia
10/11/2005US6953810 Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes
10/11/2005US6953809 Monocyte chemoattractant protein-1 inhibitor compounds
10/11/2005US6953798 compounds are able to inhibit binding of alpha 4 integrins to their ligands and are of use in prophylaxis and treatment of immune or inflammatory disorders
10/11/2005US6953796 Use of 2-amino-thiazoline derivatives as inhibitors of inducible No-synthase
10/11/2005US6953793 For therapy of autoimmune diseases mediated by cathepsin S; for inhibiting the progression of tissue transplant rejection
10/11/2005US6953792 Cyclohexyl derivatives and their use as therapeutic agents
10/11/2005US6953790 CGRP receptor antagonists
10/11/2005CA2282277C Atropisomers of 3-aryl-4(3h)-quinazolinones and their use as ampa-receptor antagonists
10/06/2005WO2005092899A1 Inhibitors of histone deacetylase
10/06/2005WO2005092894A1 Fused pyrazole derivatives as tgf-beta signal transduction inhibitors for the treatment of fibrosis and neoplasms
10/06/2005WO2005092888A1 Compound having oxadiazole ring structure substituted with pyridyl group, and organic electroluminescent device
10/06/2005WO2005092887A1 Compounds for the treatment of diseases
10/06/2005WO2005092856A1 Tetrahydrocarbazoles and derivatives
10/06/2005WO2005092845A1 Substituted heteroaryl- and phenylsulfamoyl compounds
10/06/2005WO2005092099A1 Hiv integrase inhibitors
10/06/2005WO2005073216A3 Hcv ns-3 serine protease inhibitors
10/06/2005WO2004072031A8 Phenylacetamides and their use as glucokinase modulators
10/06/2005US20050222414 N-(4-methylphenyl)-4-[4-[[(phenylmethoxy)amino]carbonyl]phenyl]-1-piperazinecarboxamide; anticarcinogenic, antiproliferative agent; ovarian carcinoma, psoriasis; gene transcription control
10/06/2005US20050222408 Administering to a tuberculosis patient a therapeutically effective amount of N-(4-methoxybenzyl)-5-nitrofuran-2-carboxamide or other derivatives of heterocyclic amides
10/06/2005US20050222255 Process for producing trans-4-amino-1-cyclohexanecarboxilic acid derivative
10/06/2005US20050222236 Viral polymerase inhibitors
10/06/2005US20050222228 Novel diazine derivatives
10/06/2005US20050222201 such as 3-(2-chloro-4-quinolinyl)-2,5-dimethyl-1H-indole-1-acetic acid, used for treating respiratory system disorders and as inhibitors of G protein-coupled receptor chemoattractant homologous receptor expressed on lymphocyte cells (CRTH2)
10/06/2005US20050222190 1,4-bis-N-oxide azaanthracenediones and the use thereof
10/06/2005US20050222189 Oxa-and thiadiazoles and their use as metalloproteinase inhibitors
10/06/2005US20050222186 Substituted diaminopyrimidines
10/06/2005US20050222181 Compounds in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
10/06/2005US20050222159 2,3-dihydropyridazin-3-ones e.g. 3-amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridazinyl)-5-phenyl-2-pyrazinecarboxamide; adenosine antagonists; depression, dementia, Parkinson's disease, anxiety, pain, hypertension, obesity, gout, bronchial asthma
10/06/2005US20050222152 Enzyme inhibitors for disease treatment with Cathepsin s
1 ... 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 ... 647